Metformin does not affect cancer risk

A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial

Konstantinos K. Tsilidis, Despoina Capothanassi, Naomi E. Allen, Evangelos C. Rizos, David Lopez, Karin Van Veldhoven, Carlotta Sacerdote, Deborah Ashby, Paolo Vineis, Ioanna Tzoulaki, John P.A. Ioannidis

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

OBJECTIVE: Meta-analyses of epidemiologic studies have suggested that metformin may reduce cancer incidence, but randomized controlled trials did not support this hypothesis. RESEARCH DESIGN AND METHODS A retrospective cohort study, Clinical Practice Research Datalink, was designed to investigate the association between use of metformin compared with other antidiabetes medications and cancer risk by emulating an intention-to-treat analysis as in a trial. A total of 95,820 participants with type 2 diabetes who started taking metformin and other oral antidiabetes medications within 12 months of their diagnosis (initiators) were followed up for first incident cancer diagnosis without regard to any subsequent changes in pharmacotherapy. Cox proportional hazards models were used to estimate multivariable-adjusted hazard ratios (HR) and 95% CI. RESULTS: A total of 51,484 individuals (54%) were metformin initiators and 18,264 (19%) were sulfonylurea initiators, and 3,805 first incident cancers were diagnosed during a median follow-up time of 5.1 years. Compared with initiators of sulfonylurea, initiators of metformin had a similar incidence of total cancer (HR 0.96; 95% CI 0.89-1.04) and colorectal (HR 0.92; 95% CI 0.76-1.13), prostate (HR 1.02; 95% CI 0.83-1.25), lung (HR 0.85; 95% CI 0.68-1.07), or postmenopausal breast (HR 1.03; 95% CI 0.82-1.31) cancer or any other cancer. CONCLUSIONS: In this large study, individualswith diabetes who usedmetformin had a similar risk of developing cancer compared with those who used sulfonylureas.

Original languageEnglish (US)
Pages (from-to)2522-2532
Number of pages11
JournalDiabetes care
Volume37
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Metformin
Cohort Studies
Research
Neoplasms
Intention to Treat Analysis
Incidence
Proportional Hazards Models
Type 2 Diabetes Mellitus
Meta-Analysis
Epidemiologic Studies
Prostate
Breast
Research Design
Randomized Controlled Trials
Retrospective Studies
Drug Therapy
Lung

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Tsilidis, K. K., Capothanassi, D., Allen, N. E., Rizos, E. C., Lopez, D., Van Veldhoven, K., ... Ioannidis, J. P. A. (2014). Metformin does not affect cancer risk: A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial. Diabetes care, 37(9), 2522-2532. https://doi.org/10.2337/dc14-0584

Metformin does not affect cancer risk : A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial. / Tsilidis, Konstantinos K.; Capothanassi, Despoina; Allen, Naomi E.; Rizos, Evangelos C.; Lopez, David; Van Veldhoven, Karin; Sacerdote, Carlotta; Ashby, Deborah; Vineis, Paolo; Tzoulaki, Ioanna; Ioannidis, John P.A.

In: Diabetes care, Vol. 37, No. 9, 01.01.2014, p. 2522-2532.

Research output: Contribution to journalArticle

Tsilidis, KK, Capothanassi, D, Allen, NE, Rizos, EC, Lopez, D, Van Veldhoven, K, Sacerdote, C, Ashby, D, Vineis, P, Tzoulaki, I & Ioannidis, JPA 2014, 'Metformin does not affect cancer risk: A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial', Diabetes care, vol. 37, no. 9, pp. 2522-2532. https://doi.org/10.2337/dc14-0584
Tsilidis, Konstantinos K. ; Capothanassi, Despoina ; Allen, Naomi E. ; Rizos, Evangelos C. ; Lopez, David ; Van Veldhoven, Karin ; Sacerdote, Carlotta ; Ashby, Deborah ; Vineis, Paolo ; Tzoulaki, Ioanna ; Ioannidis, John P.A. / Metformin does not affect cancer risk : A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial. In: Diabetes care. 2014 ; Vol. 37, No. 9. pp. 2522-2532.
@article{9c9975de76054b459942f524d766e487,
title = "Metformin does not affect cancer risk: A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial",
abstract = "OBJECTIVE: Meta-analyses of epidemiologic studies have suggested that metformin may reduce cancer incidence, but randomized controlled trials did not support this hypothesis. RESEARCH DESIGN AND METHODS A retrospective cohort study, Clinical Practice Research Datalink, was designed to investigate the association between use of metformin compared with other antidiabetes medications and cancer risk by emulating an intention-to-treat analysis as in a trial. A total of 95,820 participants with type 2 diabetes who started taking metformin and other oral antidiabetes medications within 12 months of their diagnosis (initiators) were followed up for first incident cancer diagnosis without regard to any subsequent changes in pharmacotherapy. Cox proportional hazards models were used to estimate multivariable-adjusted hazard ratios (HR) and 95{\%} CI. RESULTS: A total of 51,484 individuals (54{\%}) were metformin initiators and 18,264 (19{\%}) were sulfonylurea initiators, and 3,805 first incident cancers were diagnosed during a median follow-up time of 5.1 years. Compared with initiators of sulfonylurea, initiators of metformin had a similar incidence of total cancer (HR 0.96; 95{\%} CI 0.89-1.04) and colorectal (HR 0.92; 95{\%} CI 0.76-1.13), prostate (HR 1.02; 95{\%} CI 0.83-1.25), lung (HR 0.85; 95{\%} CI 0.68-1.07), or postmenopausal breast (HR 1.03; 95{\%} CI 0.82-1.31) cancer or any other cancer. CONCLUSIONS: In this large study, individualswith diabetes who usedmetformin had a similar risk of developing cancer compared with those who used sulfonylureas.",
author = "Tsilidis, {Konstantinos K.} and Despoina Capothanassi and Allen, {Naomi E.} and Rizos, {Evangelos C.} and David Lopez and {Van Veldhoven}, Karin and Carlotta Sacerdote and Deborah Ashby and Paolo Vineis and Ioanna Tzoulaki and Ioannidis, {John P.A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2337/dc14-0584",
language = "English (US)",
volume = "37",
pages = "2522--2532",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Metformin does not affect cancer risk

T2 - A cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial

AU - Tsilidis, Konstantinos K.

AU - Capothanassi, Despoina

AU - Allen, Naomi E.

AU - Rizos, Evangelos C.

AU - Lopez, David

AU - Van Veldhoven, Karin

AU - Sacerdote, Carlotta

AU - Ashby, Deborah

AU - Vineis, Paolo

AU - Tzoulaki, Ioanna

AU - Ioannidis, John P.A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - OBJECTIVE: Meta-analyses of epidemiologic studies have suggested that metformin may reduce cancer incidence, but randomized controlled trials did not support this hypothesis. RESEARCH DESIGN AND METHODS A retrospective cohort study, Clinical Practice Research Datalink, was designed to investigate the association between use of metformin compared with other antidiabetes medications and cancer risk by emulating an intention-to-treat analysis as in a trial. A total of 95,820 participants with type 2 diabetes who started taking metformin and other oral antidiabetes medications within 12 months of their diagnosis (initiators) were followed up for first incident cancer diagnosis without regard to any subsequent changes in pharmacotherapy. Cox proportional hazards models were used to estimate multivariable-adjusted hazard ratios (HR) and 95% CI. RESULTS: A total of 51,484 individuals (54%) were metformin initiators and 18,264 (19%) were sulfonylurea initiators, and 3,805 first incident cancers were diagnosed during a median follow-up time of 5.1 years. Compared with initiators of sulfonylurea, initiators of metformin had a similar incidence of total cancer (HR 0.96; 95% CI 0.89-1.04) and colorectal (HR 0.92; 95% CI 0.76-1.13), prostate (HR 1.02; 95% CI 0.83-1.25), lung (HR 0.85; 95% CI 0.68-1.07), or postmenopausal breast (HR 1.03; 95% CI 0.82-1.31) cancer or any other cancer. CONCLUSIONS: In this large study, individualswith diabetes who usedmetformin had a similar risk of developing cancer compared with those who used sulfonylureas.

AB - OBJECTIVE: Meta-analyses of epidemiologic studies have suggested that metformin may reduce cancer incidence, but randomized controlled trials did not support this hypothesis. RESEARCH DESIGN AND METHODS A retrospective cohort study, Clinical Practice Research Datalink, was designed to investigate the association between use of metformin compared with other antidiabetes medications and cancer risk by emulating an intention-to-treat analysis as in a trial. A total of 95,820 participants with type 2 diabetes who started taking metformin and other oral antidiabetes medications within 12 months of their diagnosis (initiators) were followed up for first incident cancer diagnosis without regard to any subsequent changes in pharmacotherapy. Cox proportional hazards models were used to estimate multivariable-adjusted hazard ratios (HR) and 95% CI. RESULTS: A total of 51,484 individuals (54%) were metformin initiators and 18,264 (19%) were sulfonylurea initiators, and 3,805 first incident cancers were diagnosed during a median follow-up time of 5.1 years. Compared with initiators of sulfonylurea, initiators of metformin had a similar incidence of total cancer (HR 0.96; 95% CI 0.89-1.04) and colorectal (HR 0.92; 95% CI 0.76-1.13), prostate (HR 1.02; 95% CI 0.83-1.25), lung (HR 0.85; 95% CI 0.68-1.07), or postmenopausal breast (HR 1.03; 95% CI 0.82-1.31) cancer or any other cancer. CONCLUSIONS: In this large study, individualswith diabetes who usedmetformin had a similar risk of developing cancer compared with those who used sulfonylureas.

UR - http://www.scopus.com/inward/record.url?scp=84906691535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906691535&partnerID=8YFLogxK

U2 - 10.2337/dc14-0584

DO - 10.2337/dc14-0584

M3 - Article

VL - 37

SP - 2522

EP - 2532

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -